Fresenius Medical Care AG

FME

DE0005785802

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:36:59 2024-04-16 am EDT			After market 03:59:47 pm
34.99 ^EUR	-1.16%		35.09	+0.29%

11:12am	Fresenius at a two-month high - Tyenne launch and fantasy figures	DP
10:28am	Fresenius at two-month high - Tyenne launch a milestone	DP

FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Receives a Buy rating from Barclays

July 30, 2020 at 08:39 am EDT

Analyst Hassan Al-Wakeel from Barclays research considers the stock attractive and recommends it with a Buy rating. The target price is unchanged and still at EUR 88.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	BARCLAYS PLC	178.5 GBX	-2.54%	-5.52%	34.29B
	FRESENIUS SE & CO. KGAA	26.61 EUR	+4.56%	+4.85%	15.24B

Latest news about Fresenius Medical Care AG

Fresenius at a two-month high - Tyenne launch and fantasy figures	05:12am	DP
Fresenius at two-month high - Tyenne launch a milestone	04:28am	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
FMC FRESENIUS MEDICAL CARE AG & CO KGAA : JP Morgan gives a Sell rating	Apr. 04	ZD
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device	Mar. 19	CI
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024	Mar. 13	CI
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	Mar. 06	MT
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	Mar. 05	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 05	MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon	Mar. 05	MT
Fresenius Medical Care to Sell Dialysis Clinics in Brazil, Colombia, Chile, Ecuador to DaVita	Mar. 05	MT
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data	Mar. 05	RE
European Equities Traded in the US as American Depositary Receipts Decline Tuesday	Mar. 05	MT
FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Barclays reaffirms its Neutral rating	Mar. 05	ZD
FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Berenberg keeps its Buy rating	Mar. 05	ZD
Dialysis firms gain as Ozempic kidney trial data disappoints	Mar. 05	RE
Novo Nordisk's kidney trial cuts cardiac risk, death by 24%	Mar. 05	RE
Novo Nordisk Ozempic trial delays progression of chronic kidney disease	Mar. 05	RE
DaVita Inc. agreed to acquire Dialysis clinic networks in Colombia from Fresenius Medical Care AG.	Mar. 04	CI
DaVita Inc. agreed to acquire Dialysis clinic networks in Chile from Fresenius Medical Care AG.	Mar. 04	CI

Chart Fresenius Medical Care AG

Duration

Period

More charts

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

Sector

Healthcare Facilities & Services

Calendar

2024-05-06 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS MEDICAL CARE : Barebone 2023 profitability is a much lower starting point

February 21, 2024 at 04:12 am EST

More Strategies

Ratings for Fresenius Medical Care AG

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

35.4 EUR

Average target price

38.95 EUR

Spread / Average Target

+10.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS MEDICAL CARE AG	-7.82%	11.04B
CVS HEALTH CORPORATION	-12.58%	86.92B
HCA HEALTHCARE, INC.	+15.96%	85.34B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+12.75%	29.88B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.16%	17.1B
FRESENIUS SE & CO. KGAA	-5.20%	15.24B
QUEST DIAGNOSTICS INCORPORATED	-7.59%	14.29B
EUROFINS SCIENTIFIC SE	+0.27%	12.38B
PURE HEALTH HOLDING	-31.58%	12.1B
DAVITA INC.	+23.88%	11.4B

Other Healthcare Facilities & Services

Fresenius Medical Care AG

Equities

FME

DE0005785802

Healthcare Facilities & Services

FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Receives a Buy rating from Barclays

Stocks mentioned in the article

EPS Revisions